Furthermore, Ring and colleagues have revealed a new anti-human SIRPα antibody, KWAR23, which can elevate both neutrophils and macrophages’ anti-tumor activity in vitro and in vivo (227). This evidence concerns the gene SIRPA and neoplasm.